A carregar...
1659. Pharmacokinetics/pharmacodynamics of the Novel Gyrase Inhibitor SPR719/SPR720 and Clinical Dose Selection to Treat Pulmonary Mycobacterium avium-complex Disease
BACKGROUND: Current therapy for pulmonary Mycobacterium avium-complex [MAC] disease achieves poor sustained sputum conversion rates and is poorly tolerated. SPR719, the active metabolite of SPR720, a novel gyrase inhibitor, has demonstrated low MICs against MAC. SPR720 is being developed as an oral...
Na minha lista:
| Publicado no: | Open Forum Infect Dis |
|---|---|
| Main Authors: | , , , , , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
Oxford University Press
2020
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7777696/ https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/ofid/ofaa439.1837 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|